Entering text into the input field will update the search result below

Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2020 Results - Earnings Call Transcript

May 05, 2020 9:58 PM ETTheriva Biologics, Inc. (TOVX)
SA Transcripts profile picture
SA Transcripts

Synthetic Biologics, Inc. (SYN) Q1 2020 Earnings Conference Call May 5, 2020 4:30 PM ET

Company Participants

Vincent Perrone – Director-Corporate Communication

Steven Shallcross – Chief Executive and Financial Officer

Vince Wacher – Head-Product and Corporate Development

Conference Call Participants

James Molloy – Alliance Global Partners

Michael Okunewitch – Maxim Group


Good afternoon and welcome to the Synthetic Biologics' 2020 First Quarter Investor Conference Call.

At this time, I would like to turn the call over to Vincent Perrone, Director, Corporate Communication at Synthetic Biologics. Please go ahead, Vincent.

Vincent Perrone

Thank you, Taylor and good afternoon everyone. Welcome to Synthetic Biologics 2020 first quarter investor conference call. Today, I'm joined remotely by our Chief Executive and Financial Officer, Steven Shallcross; Dr. Michael Kaleko, Senior Vice President of Research and Development; and Dr. Vince Wacher, Head of Product and Corporate Development.

Synthetic Biologics issued a press release this afternoon, which provided operational highlights and reported our financial results for the quarter ending March 31, 2020. The release can be found on the Investor Relations section of our website.

During our call today, we'll provide an operational update on our GI and microbiome-focused clinical programs and summarize our financial results. We'll take questions after prepared remarks. In addition to the phone line, this call is being streamed live via webcast, which will be archived on our website, syntheticbiologics.com for 90 days.

During this call, we will be making forward-looking statements regarding Synthetic Biologics' current expectations and projections about future events. Generally, the forward-looking statements can be identified by terminology such as may, should, expects, anticipates, intends, plans, believes and estimates and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, including those set forth in Synthetic Biologics' filings with the SEC, many of which are difficult to predict. No forward-looking statements can be

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About TOVX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on TOVX

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.